Waldron Private Wealth LLC Sells 78 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Waldron Private Wealth LLC trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.3% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 288 shares of the biopharmaceutical company’s stock after selling 78 shares during the quarter. Waldron Private Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $205,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Rakuten Securities Inc. grew its stake in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares during the last quarter. FSA Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter worth about $26,000. Fairfield Financial Advisors LTD bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $37,000. Truvestments Capital LLC bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $39,000. Finally, Valley Wealth Managers Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $49,000. 83.31% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

REGN has been the topic of several research analyst reports. JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. Finally, Barclays cut their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,004.57.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $672.98 on Monday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $666.25 and a twelve month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a 50-day simple moving average of $720.81 and a two-hundred day simple moving average of $922.87. The stock has a market capitalization of $73.95 billion, a price-to-earnings ratio of 16.65, a price-to-earnings-growth ratio of 1.62 and a beta of 0.10.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.